Table 1. Open in new tab Summary of our...

Table 1.

Summary of our study cohort including various cases of dermatomyositis/polymyositis after COVID-19 vaccinations.

No.	Age	Sex	Antibody	Type of vaccine/manufacturer	Number of doses	Time to onset after vaccination	Gottron’s sign	Skin lesions
1	37	Female	PM-Scl	Vector/AstraZeneca	1	4 days	−	+
2	74	Male	None	Vector/AstraZeneca	1	2 days	−	−
3	75	Female	None	Vector/AstraZeneca	1	2 days	−	−
4	80	Female	None	Vector/AstraZeneca	2	2 days	−	−
5	46	Female	Jo-1, Ro-52	Vector/AstraZeneca	2	1 week	−	+
6	47	Female	None	mRNA/Moderna	2	3 days	−	+
7	51	Male	None	mRNA/Moderna	2	6 days	+	+
8	26	Male	None	mRNA/Moderna	2	7 days	+	+
9	55	Female	Mi-2, Ro-52	mRNA/Pfizer	1	2 days	−	+
10	72	Female	Fibrillarin	mRNA/Pfizer	2	1 day	−	−
11	43	Female	RNP	mRNA/Pfizer	2	10 days	−	+
12	53	Male	NXP-2	mRNA/Pfizer	2	2 weeks	−	+
13	30	Male	None	mRNA/Pfizer	2	6 days	+	+
14	77	Female	TIF-1γ	mRNA/Pfizer	1	5 days	−	+
15^a	62	Female	MDA-5	mRNA/Pfizer	3	6 days	+	+

No.	Age	Sex	Antibody	Type of vaccine/manufacturer	Number of doses	Time to onset after vaccination	Gottron’s sign	Skin lesions
1	37	Female	PM-Scl	Vector/AstraZeneca	1	4 days	−	+
2	74	Male	None	Vector/AstraZeneca	1	2 days	−	−
3	75	Female	None	Vector/AstraZeneca	1	2 days	−	−
4	80	Female	None	Vector/AstraZeneca	2	2 days	−	−
5	46	Female	Jo-1, Ro-52	Vector/AstraZeneca	2	1 week	−	+
6	47	Female	None	mRNA/Moderna	2	3 days	−	+
7	51	Male	None	mRNA/Moderna	2	6 days	+	+
8	26	Male	None	mRNA/Moderna	2	7 days	+	+
9	55	Female	Mi-2, Ro-52	mRNA/Pfizer	1	2 days	−	+
10	72	Female	Fibrillarin	mRNA/Pfizer	2	1 day	−	−
11	43	Female	RNP	mRNA/Pfizer	2	10 days	−	+
12	53	Male	NXP-2	mRNA/Pfizer	2	2 weeks	−	+
13	30	Male	None	mRNA/Pfizer	2	6 days	+	+
14	77	Female	TIF-1γ	mRNA/Pfizer	1	5 days	−	+
15^a	62	Female	MDA-5	mRNA/Pfizer	3	6 days	+	+

RNP, ribonucleoprotein; NXP-2, nuclear matrix protein 2; TIF-1γ, transcription intermediary factor 1γ; +, existence; −, none.

This case is in bold the one we experienced.